Carb Cravings Control
One of the things that I remain most impressed by is the way this community has banded together, both here and on my Facebook page. I’m amazed at how supportive everyone is, and the valuable discussion that takes place. That’s why I wanted to use this blog post to pose a question to all of you: how do you handle your carb cravings? Last week, I mentioned that gluten and sugar can act much like a drug, leaving those going off gluten, grains and sugar going through a period of “withdrawal.” I’ve seen a number of comments come in from folks looking for advice on how to deal with this period and prevent a slip-up. Better than answering this myself, I thought this was the perfect question to pose to all of you, as many of you may have just gone through this phase yourself. How did you handle the cravings? What did you do to overcome them? Is there a snack, an exercise or a mantra? Share your tips and tricks with others. I’m interested to see what everyone has to say! The post Carb Cravings Control appeared first on David Perlmutter M.D..
AbstractBackgroundPrevious studies have identified that patients withEGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT) ‐related outcomes has not been fully assessed. We studied the impact of common non‐small cell lung cancer (NSCLC) genetic alterations (EGFR,ALK andKRAS) in relation to objective response rate (ORR) to RT in patients with brain metastases.MethodsFrom 2009 –2015, 153 patients with an available genotyping status were treated with whole‐brain irradiation (WBI) before receiving systemic ...
ConclusionsEndostar delivered by CIV with CCRT may be a better option than IV in terms of potential survival and safety for unresectable stage III NSCLC.Key pointsSignificant findings of the study Endostar delivered by continuous intravenous pumping might achieve more favorable survival over intravenous injection and reduce adverse hematological reactions in patients with unresectable stage III NSCLC treated with Endostar combined with CCRT.What this study adds The administration route of recombinant human endostatin is also one key factor for survival and safety to consider when treating patients with unresectable stage III NSCLC.
ConclusionsThe use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboringEGFR mutation acquired T790M resistance.
Authors: Dietrich DE, Bode L, Spannhuth CW, Hecker H, Ludwig H, Emrich HM Abstract BACKGROUND: Whether Borna disease virus (BDV-1) is a human pathogen remained controversial until recent encephalitis cases showed BDV-1 infection could even be deadly. This called to mind previous evidence for an infectious contribution of BDV-1 to mental disorders. Pilot open trials suggested that BDV-1 infected depressed patients benefitted from antiviral therapy with a licensed drug (amantadine) which also tested sensitive in vitro. Here, we designed a double-blind placebo-controlled randomized clinical trial (RCT) which cross-lin...
Date: Friday, 02 28, 2020; Speaker: Jonathan Wasserman, Staff Physician, SickKids; BG 10-CRC; FAES 1&2
Date: Tuesday, 03 03, 2020; Speaker: TBD, TBD; Dr. Jeremy Veenstra-VanderWeele, Columbia University; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Date: Tuesday, 03 10, 2020; Speaker: TBD, TBD; Dr. Jeff Elias, University of Virginia School of Medicine; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Date: Tuesday, 03 10, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); NIH Library Training Room
Date: Wednesday, 03 11, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); This class is presented as a webinar only; Videocast Event
Date: Thursday, 03 12, 2020; Speaker: BTRIS instructor; Building: Building 10 (Clinical Center); NIH Library Training Room